$29.99-1.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Just reported
From Immunocore Holdings plc's results release of November 6, 2026; its quarterly report has since been filed.
Actual
$102.2M
-1.4% y/y
-12% q/q
Guided
—
No guide given
Actual
-$0.28
Guided
—
No guide given
Actual
-$13.6M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $102.2M | $103.7M | -1.42% |
| Profit | -$14.2M | -$177K | -7,935.03% |
| Profit per share | -$0.28 | $0.00 | — |
| Free Cash Flow | $17.7M | -$5.2M | +440.97% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Immunocore Holdings plc reported on November 6, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
TM molecules and autoimmune diseases ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress pathogenic T cells via PD1 receptor agonism while minimizing the risk of systemic immune suppression. The Company is currently advancing two candidates for autoimmune diseases, including type 1 diabetes and inflammatory dermatological diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Immunocore Holdings plc’s Item 2.02 8-K filed November 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.